No new information was released, the reaffirmation simply reiterates existing targets. Monitor upcoming quarterly filings for any deviation from the reaffirmed guidance range, particularly around medical cost trends reflected in the 90.2% benefit expense ratio.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 10 $404.56entry
- T+1 · 5mo ago −1.33%α −3.03% · $399.18
- T+5 · 5mo ago −1.67%α −5.10% · $397.80
- T+20 · 4mo ago +3.91%α +0.29% · $420.39
- T+60 · 2mo ago +2.53%α −4.05% · $414.78
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Elevance Health filed an 8-K to publicly reaffirm its full-year 2026 guidance during investor meetings this week. The company confirmed adjusted EPS of at least $26.75 (and GAAP EPS of at least $19.85) and a benefit expense ratio of 90.2% ±50bps. This is a routine FD disclosure with no new financial data or revisions, merely a reiteration of previously stated targets.
Key Facts
- Management reaffirmed full-year 2026 GAAP EPS of at least $19.85 per share, including ~$6.90/share of net unfavorable items.
- Adjusted (non-GAAP) EPS reaffirmed at at least $26.75 per share.
- Full-year 2026 benefit expense ratio guidance reaffirmed at 90.2% plus or minus 50 basis points.
- Guidance does not include any adjustment items beyond those reported in Q1 2026 earnings.
- Filing is a Regulation FD disclosure of investor meeting talking points; no change to prior guidance.
Financial Impact
No financial figures were changed or revised. Reaffirmation of existing guidance at the same levels as previously communicated.
Risk Factors
- Medical cost trends could deviate from the 90.2% guidance band, pressuring margins.
- Macroeconomic or regulatory changes could impact enrollment and premium adequacy.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001156039-26-000049 |
| Document: 0001156039-26-000049-index-headers.html | 0001156039-26-000049 |
| Document: 0001156039-26-000049-index.html | 0001156039-26-000049 |
| Document: 0001156039-26-000049.txt | 0001156039-26-000049 |
Track record
19 reports on ELV
1 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +3.93% at T+5 after the Aug 27, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $429.48 Now $446.28 +3.91% settles Nov 18
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $425.62 to $429.69 Now $446.28 +4.85% ▲ +0.96% −1.64% vs SPY
- Oct 28, 202619d ago S-3ASR Neutral 3/10 Entry $422.02 to $432.00 Now $446.28 +5.75% ▲ +2.36% +7.09% vs SPY
- Oct 22, 202625d ago 144 Neutral 2/10 Entry $439.95 to $420.07 Now $446.28 +1.44% ▼ −4.52% −3.96% vs SPY
- Oct 21, 202626d ago 8-K Bullish 7/10 Entry $434.13 to $421.49 Now $446.28 +2.80% ▼ −2.91% −2.47% vs SPY
- Oct 20, 202627d ago Institutional Cluster Neutral 3/10 Entry $434.13 to $421.49 Now $446.28 +2.80% ▼ −2.91% −2.47% vs SPY
- Sep 10, 20269w ago 8-K Neutral 3/10 Entry $416.54 to $414.26 Now $446.28 +7.14% ▼ −0.55% −0.05% vs SPY
- Aug 27, 202611w ago Institutional Cluster Bullish 6/10 Entry $399.11 to $414.78 Now $446.28 +11.82% ▲ +3.93% +3.66% vs SPY
- Aug 20, 202612w ago Court Ruling Neutral 2/10 Entry $400.54 to $394.43 Now $446.28 +11.42% ▼ −1.53% −2.00% vs SPY
- Aug 17, 202613w ago Court Ruling Neutral 1/10 Entry $396.54 to $397.14 Now $446.28 +12.54% ▲ +0.15% +0.35% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers